Clinical Trial Update: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab plus olaparib for endometrial cancer and endometrial carcinosarcoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Carcinosarcoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Endometrial Carcinosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING